Abstract
Prostate cancer is a leading cause of cancer death in men. Advanced disease may progress to metastatic castration-resistant prostate cancer. In March 2022, 177Lu-vipivotide tetraxetan was U.S. Food and Drug Administration-approved for patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have previously received other therapies, including androgen deprivation and taxane therapies. Methods: Although preliminary data for 177Lu-vipivotide tetraxetan has shown extension of overall survival of patients, there is little literature about realistically initiating 177Lu-vipivotide tetraxetan into non-academic-based clinical practices. Results: This article presents a multidisciplinary practice implementation workflow for 177Lu-vipivotide tetraxetan. It also highlights the challenges and considerations for initiating such a theranostics practice. Conclusion: The aim of this work is to help nontertiary medical centers improve patient accessibility for beneficial radiopharmaceutical therapies, specifically 177Lu-vipivotide tetraxetan.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call